(A) Expression of P2RX7 on NK cells and ILC1 in the liver (n = 3–5). (B) Plasma concentration of extracellular ATP from the proximal inferior vena cava before (naïve) and 15 h after CCl4 injection. Data were pooled from 2 experiments (n = 6–10). (C) Expression of CD25 on NK cells and ILC1 in the liver of mice (that had been injected or not with BBG) before and 18 h after CCl4 injection (n = 2–5). (D) Expression of CD69 on NK cells, CD25− ILC1, and CD25+ ILC1 in the liver of mice (that had been injected or not with BBG) before and 18 h after CCl4 injection (n = 2–5). (E) The percentages of IFN-γ+ cells in ILC1, CD25− ILC1, and CD25+ ILC1 in the liver of mice (that had been injected or not with BBG) before and 15 h after CCl4 injection (n = 2–5). (F) The percentages of IFN-γ+ cells in NK cells, CD25− ILC1, and CD25+ ILC1 in the liver of mice (that had been injected or not with BBG) before and 15 h after CCl4 injection. Data were pooled from 2 experiments (n = 5–10). (G) Plasma concentration of ALT in mice (that had been injected or not with BBG) before and 18 h after CCl4 injection. Data were pooled from 2 experiments (n = 4–8). (H) Expression of Il12a and Il12b mRNA in the liver before and 18 h after CCl4 injection (n = 3–4). (I) Expression of Il12a and Il12b mRNA in myeloid cell subsets (CD11b− DC, CD11b+ DC, Kupffer cells (KC), and macrophages (Mϕ)) in the liver before and 18 h after CCl4 injection. Data were pooled from 3 experiments (n = 4–5). (J) The percentages of IFN-γ+ cells in liver NK cells and liver ILC1 after stimulation with or without IL-12, ATP or both. Data were pooled from 2 experiments (n = 6). (K) The percentages of IFN-γ+ cells in liver NK cells, liver CD25− ILC1, and liver CD25+ ILC1 (isolated from mice before (naïve) and 18 h after CCl4 injection) after stimulation with or without IL-12 and ATP. Data were pooled from 3 experiments (n = 10–16). Data are representative of 7 (A) and 2 (C, D, E, and H) independent experiments. *p<0.05, **p<0.005. Error bars show s.d. See also Figure S5.